Written answers
Tuesday, 24 January 2023
Department of Health
Medicinal Products
Peadar Tóibín (Meath West, Aontú)
Link to this: Individually | In context | Oireachtas source
590. To ask the Minister for Health if Sunosi, which is produced in Ireland and has a successful record treating persons with narcolepsy, is or will be made available on the medical card; and, if so, if this drug will be prescribed by a GP or only through a hospital. [3114/23]
Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.
In October 2022, the HSE approved the drug Sunosi® (solriamfetol) for reimbursement under High Tech Arrangements subject to managed access for adult patients with narcolepsy (with or without cataplexy), in accordance with the proposed place in therapy as a second-line treatment.
However, the company that holds the marketing authorisation for Sunosi® (solriamfetol) has not yet launched the product in Ireland.
No comments